Uddin Muhammad Azhar, Rabbani Malik Anas, Jafary Fahim H, Bhatti Maqsood Ahmed, Islam Muhammad
Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan.
J Coll Physicians Surg Pak. 2005 Dec;15(12):791-4.
To determine the incidence of contrast nephropathy in high-risk patients undergoing coronary angiography and percutaneous coronary intervention (PCI), and to define the characteristics of this cohort.
Discriptive study.
The Aga Khan University Hospital, Karachi from January to December 2002.
One hundred and fifteen patients with serum creatinine greater than 1.4mg/dl who underwent coronary angiography or PCI were included. All patients received non-ionic contrast dye. Acute contrast nephropathy was defined as rise in serum creatinine of 0.5mg/dl within 48 hours following the index procedure. Means and standard deviations were calculated for continuous variables and frequencies for categorical variables.
Mean age of patients was 62.3 years +/- 8.83. Mean pre-contrast creatinine was 1.9 +/- 0.9 mg/dl. Eleven (9.65%) patients developed contrast nephropathy. 4.4% of patients with serum creatinine < 2.0 developed contrast nephropathy compared to 42.9% of patients with creatinine > 4.0(p-value 0.001). 11.9% diabetic patients developed nephropathy compared to 6.3% of non-diabetics(p-value 0.355). 11.4% of hypertensive and 3.7% of non-hypertensive patients developed contrast-nephropathy (p-value 0.454). 12.9% of low dose group(<100 ml) and 5.7% of high dose group (>100 ml) developed nephropathy (p-value 0.188). Mean serum creatinine in low dose group was higher (3.0 mg/dl vs. 1.7 mg/dl).
The incidence of contrast nephropathy in this study was similar to that reported in literature. Risk of CIN was found to be significantly proportional to the severity of baseline renal disease. Trends towards higher risk of CIN were seen in patients with diabetes and hypertension. Higher incidence of CIN in patients receiving low-dose contrast was confounded by higher baseline serum creatinine in that group.
确定接受冠状动脉造影和经皮冠状动脉介入治疗(PCI)的高危患者中对比剂肾病的发生率,并明确该队列患者的特征。
描述性研究。
2002年1月至12月在卡拉奇的阿迦汗大学医院。
纳入115例血清肌酐大于1.4mg/dl且接受冠状动脉造影或PCI的患者。所有患者均接受非离子型对比剂。急性对比剂肾病定义为在索引操作后48小时内血清肌酐升高0.5mg/dl。计算连续变量的均值和标准差以及分类变量的频率。
患者的平均年龄为62.3岁±8.83岁。对比剂注射前的平均肌酐为1.9±0.9mg/dl。11例(9.65%)患者发生对比剂肾病。血清肌酐<2.0的患者中4.4%发生对比剂肾病,而肌酐>4.0的患者中这一比例为42.9%(p值0.001)。11.9%的糖尿病患者发生肾病,而非糖尿病患者为6.3%(p值0.355)。11. %的高血压患者和3.7%的非高血压患者发生对比剂肾病(p值0.454)。低剂量组(<100ml)中12.9%的患者和高剂量组(>100ml)中5.7%的患者发生肾病(p值0.188)。低剂量组的平均血清肌酐更高(3.0mg/dl对1.7mg/dl)。
本研究中对比剂肾病的发生率与文献报道相似。发现对比剂肾病的风险与基线肾病的严重程度显著相关。糖尿病和高血压患者中对比剂肾病风险有升高趋势。接受低剂量对比剂的患者中对比剂肾病发生率较高是由于该组患者基线血清肌酐较高所致。